Key facts
- Sightstream’s last known valuation is $13.5M (Oct 2025).
- It has raised $5.1M; the latest was Later Stage VC ($2.0M) in Oct 2025.
- Notable investors include Safar Partners, ShangBay Capital, 7G Bioventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Sightstream
- ·The full record, as it builds
Funding rounds
No funding rounds for Sightstream are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sightstream
Operator of a biotechnology research company intended to reverse ocular cell death. The company develops cytoprotectives and pro-regenerative technologies that prevent and reverse the death of cells in the ocular cell system, enabling healthcare providers to help patients prevent and recover from ocular cell damage.
- Sector
- Healthcare
- HQ
- Medfield, MA, United States
- Founded
- 2020
- Employees
- 7
- Website
- sightstreambio.com/
- Ownership
- Privately Held (backing)
Sightstream doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sightstream shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sightstream in its N-PORT filings yet. We sweep new filings monthly.